Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
CABASTY trial: what clinicians have said so far
Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel
- NCT02961257 ↗
- Completed
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on CABASTY (cabazitaxel in docetaxel-treated metastatic castration-resistant prostate cancer in older men) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CABASTY so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Randomized Multicenter, Phase III Trial Evaluating the Safety of 2 Schedules of Cabazitaxel (Bi-weekly Versus Tri-weekly) Plus Prednisone in Elderly Men (≥ 65years) With mCRPC Previously Treated With a Docetaxel-containing Regimen
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Prostate Cancer Metastatic
- Interventions
- cabazitaxel; Prednisone; Granulocyte colony-stimulating factor (G-CSF)
- Arms
- Arm A · Experimental
- Arm B · Experimental
- Enrollment
- 196
- Primary outcomes
- Number of grade ≥ 3 neutropenia and/or neutropenic complications
- Sponsor
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
- Start
- May 5, 2017
- Primary completion
- Dec 2, 2021
- Results posted
- No
- Registry record
- NCT02961257 · updated May 12, 2022
Publications
linked from the registry- Vauchier C, Thibault C, Velev M, Becker O, Guillaume Z, Ashton E, Zaibet S, Berthou H, Courtinat F, Gervais C, Rochand A, Robbrecht D, Oudard S, Auclin E. Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel - A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 Trials. Eur Urol Oncol. 2026 Apr 21:S2588-9311(26)00081-7. doi: 10.1016/j.euo.2026.03.022. Online ahead of print. PubMed 42020286
- Oudard S, Ratta R, Voog E, Barthelemy P, Thiery-Vuillemin A, Bennamoun M, Hasbini A, Aldabbagh K, Saldana C, Sevin E, Amela E, Von Amsberg G, Houede N, Besson D, Feyerabend S, Boegemann M, Pfister D, Schostak M, Huillard O, Di Fiore F, Quivy A, Lange C, Phan L, Belhouari H, Tran Y, Kotti S, Helissey C. Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial. JAMA Oncol. 2023 Dec 1;9(12):1629-1638. doi: 10.1001/jamaoncol.2023.4255. PubMed 37883073
- Pobel C, Auclin E, Procureur A, Clement-Zhao A, Simonaggio A, Delanoy N, Vano YA, Thibault C, Oudard S. Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a review. Future Oncol. 2021 Jan;17(1):91-102. doi: 10.2217/fon-2020-0672. Epub 2020 Dec 2. PubMed 33463373